Latest News - Clinical Trials

Thursday, October 26, 2017 | Clinical Trials

New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology

Aura Biosciences announced that Carol Shields, MD, Director of the Ocular Oncology Service at the Wills Eye Hospital in Philadelphia, will present data from the phase 1b clinical safety study of AU-01…

Read the full story

Wednesday, October 25, 2017 | Clinical Trials, Retina, Clearside Biomedical

Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with DME

Clearside Biomedical announced completion of patient enrollment in the phase 2 clinical trial (TYBEE) of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid triamcinolon…

Read the full story

Wednesday, October 25, 2017 | Clinical Trials, Aldeyra Therapeutics

Aldeyra Therapeutics to Present Efficacy Results of ADX-102 in Noninfectious Anterior Uveitis

Aldeyra Therapeutics announced it will present data from the previously announced phase 2 clinical trial in noninfectious anterior uveitis (NAU) demonstrating statistical noninferiority of ADX-102 to …

Read the full story

Wednesday, October 25, 2017 | Cataract Surgery, Clinical Trials, Kala Pharmaceuticals

Kala Pharmaceuticals Submits New Drug Application to FDA for Inveltys

Kala Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for Inveltys (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pa…

Read the full story

Thursday, October 19, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech Completes Patient Enrollment In Phase 2 Study Evaluating A New Delivery System for Lucentis

Genentech has completed enrollment in the LADDER (Long Acting Delivery of Ranibizumab) trial, a phase 2, multicenter, randomized, active treatment-controlled clinical trial investigatin…

Read the full story

Tuesday, October 17, 2017 | Clinical Trials

MeiraGTx Presents Preclinical Data on its Ocular Gene Therapy Studies for the Treatment of Leber's Congenital Amaurosis, Achromatopsia and X-Linked Retinitis Pigmentosa

MeiraGTx announced the presentation of preclinical data from studies in animal models of Leber's congenital amaurosis (LCA2), achromatopsia, and X-linked retinitis pigmentosa (XLRP) that support t…

Read the full story

Thursday, October 12, 2017 | Clinical Trials, Spark Therapeutics

FDA Advisory Committee Unanimously Recommends Approval of Luxturna for Patients with Biallelic RPE65-Mediated Inherited Retinal Disease

Spark Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee has unanimously recommended (16-0) approval of Luxturna (voretigene neparvovec), an investigation…

Read the full story

Wednesday, October 11, 2017 | Clinical Trials, Medical Studies, Spark Therapeutics

Spark Gene Therapy Improves Vision, At Least in Short Term: FDA

Spark Therapeutics’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review…

Read the full story

Tuesday, October 10, 2017 | Clinical Trials, Medical Studies, Retina, ThromboGenics

ThromboGenics Announces Publication in Experimental Eye Research of Preclinical Data Supporting Therapeutic Potential of THR-317 in DR

ThromboGenics NV announced that preclinical data on its THR-317 have been published in Experimental Eye Research. ThromboGenics’ preclinical studies are designed to investigate inhibition of pla…

Read the full story

Monday, October 02, 2017 | Clinical Trials, Retina

Efficacy Data on Novel Treatment for Diabetic Macular Edema

Verseon presented promising preclinical efficacy results on its plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME) at the fifth annual Targeting Ocular Disorders conference…

Read the full story

Thursday, September 28, 2017 | Clinical Trials, Retina

First Patient in US Receives a Telescope Implant for Age-Related Macular Degeneration After Previous Cataract Surgery

VisionCare announced that the first patient in its clinical investigation to evaluate the safety and effectiveness of exchanging a previously implanted IOL with the Implantable Miniature Telescope (by…

Read the full story

Thursday, September 28, 2017 | Clinical Trials, SciFluor Life Sciences

SciFluor Announces Positive Topline Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in DME Patients

SciFluor Life Sciences, a subsidiary of Allied Minds, announced positive topline results of a phase 1/2 study of SF0166, the company’s lead drug in development for the topical (eye drop) treatme…

Read the full story

Monday, September 25, 2017 | Clinical Trials

Ocugen Announces FDA Acceptance of Investigational NDA for OCU310 and Initiates Proof of Concept Study for Treatment of Dry Eye Disease

Ocugen announced that the FDA accepted its investigational new drug (IND) application for OCU310 (brimonidine/steroid combination therapy), a topical formulation for the treatment of dry eye disease (…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials, Retina, AMD, GrayBug

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet AMD

Graybug Vision announced that it has begun dosing patients with wet AMD in its first clinical trial of GB-102, its lead product. GB-102 is a novel intravitreal (IVT) injectable depot formulation of su…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials, Retina, Ophthotech

Ophthotech Provides Update on Zimura Complement Programs for Treatment of Eye Diseases

Ophthotech announced the initiation of an open-label phase 2a clinical trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macula…

Read the full story
Load More